Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […] November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Nov 2023 Blood tests for Alzheimer’s: a hit or a miss? Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […] November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Oct 2023 CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off? Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […] October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities The U.K. is rejoining the European Union’s (EU’s) $100 billion research program Horizon Europe, after being locked out of the deal amid post Brexit tensions for more than two years. This comes after months of negotiations between the U.K. government and the EU, in an attempt to broaden opportunities for researchers in the U.K.. British […] September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Sep 2023 Righting wrongs: genetic justice for Henrietta Lacks For what would have been Henrietta Lacks’ 103rd birthday last month, her family, who settled a lawsuit with Thermo Fisher – a multinational biotech company that had used her cells without seeking consent for several years – regarded the win as a “fitting day” for justice. While the settlement took place behind closed doors, where Henrietta […] September 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 25 Aug 2023Beyond Biotech podcast 60 – The cost of research On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […] August 25, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 22 Aug 2023 Lab-grown babies on the horizon: how IVG could transform human reproduction Lately, there seems to have been a lot of talk about the possibility of ‘lab-grown babies’. Proper research into this area kicked off around a decade ago, and is still largely experimental in humans. But the technique used to potentially develop lab-grown babies could hold the power to provide a novel treatment option for human […] August 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 Could a natural sweetener from hydrangeas treat Alzheimer’s disease? Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […] July 28, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2023 Diabetes drug could promote healthy aging A research team from the School of Public Health, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has provided genetic evidence that metformin might promote healthy aging using a cohort study of more than 300,000 participants of European descent (UK Biobank). The proof-of-concept work supports further clinical research into the drug repositioning […] July 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2023 Can the microbiome help the fight against infections? Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming a relationship that can range from mutually beneficial to pathogenic. To safeguard against harmful pathogens and maintain the presence of beneficial microorganisms, animals have evolved various defenses.One is small antimicrobial peptides (AMPs), small peptides that combat invading microbes. AMPs are […] July 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 21 Jul 2023 How AI is shaping clinical research and trials Artificial intelligence (AI) is everywhere at the minute, seemingly being used in some capacity in almost every professional industry, including clinical research and trials. In fact, it is fair to say that AI has taken the biotech industry by storm, and the hype surrounding it has led to numerous AI startup companies coming onto the […] July 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 CatalYm shows importance of GDF-15 in tumor immunotherapy resistance CatalYm has published preclinical data in Nature Communications that reveal the central role of Growth Differentiation Factor-15 (GDF-15) in the resistance of tumors to current immunotherapy. CatalYm said the findings further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed […] July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email